Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) is an emerging health crisis with no approved therapies. Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. However, the precise mechanisms mediating OCA effects and impact on cholesterol metabolism are not fully understood. We explored the pharmaco-toxicological effects of OCA on pathophysiological pathways in hepatocytes using a previously described perfused organotypic liver system that allows culture in near-physiological insulin/glucose milieus, and exhibits drug responses at clinically-relevant concentrations. Primary hepatocytes experienced 48 -hour exposure to OCA at concentrations approximating therapeutic (0.5μM) and supratherapeutic (10μM) levels. Global transcriptomics by RNAseq was complimented by cellular viability (MTT), CYP activity assays, and secreted FGF19 levels in the media. Dose-dependent, transcriptional effects suggested suppression of bile acid synthesis (↓CYP7A1, ↓CYP27A1) and increased bile efflux (↑ABCB4, ↑ABCB11, ↑OSTA, ↑OSTB). Pleiotropic effects included suppression of TGFβ and IL-6 signaling pathways, and signatures suggestive of HDL suppression (↑SCARB1, ↓ApoAI, ↓LCAT) and LDL elevation (↑ApoB, ↓CYP7A1). OCA exhibited direct FXR-mediated effects with increased FGF19 secretion. Transcriptomics revealed regulation of metabolic, anti-inflammatory, and anti-fibrotic pathways beneficial in NASH, and predicted cholesterol profiles consistent with clinical findings. Follow-up studies under lipotoxic/inflammatory conditions would corroborate these effects in a disease-relevant environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“This hypothesis is also supported by studies on FXR knockout mice that exhibit down-regulation of SCARB1, a key receptor for hepatic clearance of cholesterol from HDL, leading to a marked increase in HDL(Sinal et al., 2000).”
ResultStreaming fragment assignment for real-time analysis of sequencing experiments
Roberts, A., & Pachter, L. (2013) · Nature Methods · doi:10.1038/nmeth.2251 · Cited by 1,063
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 8×
“In the two decades since its discovery, the development of OCA, a ‘first-in-class’ selective FXR agonist, has gone from the laboratory to clinical studies with extensive pre-clinical and clinical characterization of its on-target effects (Hirschfield et al., 2015; Ijssennagger et al., 2016; Maneschi et al., 2013; Muda…”
BackgroundResultInfluentialSelf-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 1×
“This semi-synthetic derivative of chenodeoxycholic acid (CDA) is a farnesoid X receptor (FXR) agonist and nearly 100-fold more potent than CDA (Pellicciari et al., 2002).”
BackgroundIntestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 4×
“…FXR agonist, has gone from the laboratory to clinical studies with extensive pre-clinical and clinical characterization of its on-target effects (Hirschfield et al., 2015; Ijssennagger et al., 2016; Maneschi et al., 2013; Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015; Sanyal et al.,…”
BackgroundMethodInfluentialROAST: rotation gene set tests for complex microarray experiments
Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M.-L., Visvader, J. E., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq401 · Cited by 560
Bile acid nuclear receptor FXR and digestive system diseases
Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258 · cited 2×
“…from the laboratory to clinical studies with extensive pre-clinical and clinical characterization of its on-target effects (Hirschfield et al., 2015; Ijssennagger et al., 2016; Maneschi et al., 2013; Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015; Sanyal et al., 2009; Verbeke et al., 2014).”
BackgroundDevelopment of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153 · cited 9×
“Analysis of the transcriptomic responses at both doses using the relative similarity index (RSI) methods describedpreviously (Cole et al., 2015; Feaver et al., 2016), revealed that a majority of the differentially expressed genes (DEGs) were regulated in the same direction (2238 genes; RSI N 0.74)…”
BackgroundMethodInfluentialSelf-citationHemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro
Dash, A., Simmers, M. B., Deering, T. G., Berry, D. J., Feaver, R. E., Hastings, N. E., Pruett, T. L., LeCluyse, E. L., Blackman, B. R., & Wamhoff, B. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2012 · Cited by 108
Self-citationTerelius, Y., Figler, R. A., Marukian, S., Collado, M. S., Lawson, M. J., Mackey, A. J., Manka, D., Qualls, C. W., Blackman, B. R., Wamhoff, B. R., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.11.023 · Cited by 33
Self-citation
Cited by
Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Azizsoltani, A., Niknam, B., Taghizadeh-Teymorloei, M., Ghoodjani, E., Dianat-Moghadam, H., & Alizadeh, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118249 · Cited by 15
Metadata
- Authors
- Dash, A., Figler, R. A., Blackman, B. R., Marukian, S., Collado, M. S., Lawson, M. J., Hoang, S. A., Mackey, A. J., Manka, D., Cole, B. K., Feaver, R. E., Sanyal, A. J., & Wamhoff, B. R.
- Venue
- Toxicology in Vitro
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 39
- Pages
- 93-103
- ISSN
- 0887-2333 (ISSN-L)
- OpenAlex
- W2560147968
- Cited by
- 36
- References
- 13
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.